Table 7.
Reports of conversion surgery for unresectable pancreatic cancer
| Author | Year | Study design | n | Resectability | Treatment regimen | Conversion | Not resected | P | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RR, % | Margin‐negative rate, % | MST, mo | MST, mo | |||||||
| Nanda 181 | 2015 | Retr | 29 | BR/LA | FFX + SBRT | 41.3 | 83.0 | ‐ | ‐ | |
| Reni 184 | 2017 | Retr | 223 | BR/LA | GEM based | 27.0 | ‐ | 30 | 16.5 | <.00001 |
| Veldhuisen 37 | 2018 | Retr | 54 | BR/LA | FFX | 20.3 | 55 | 29 | 16 | .02 |
| Maggino 192 | 2019 | Pros | 680 | BR/LA | FFX/GnP/others | 15.1 | 57.8 | 41.8 | ‐ | |
| Yoo 189 | 2019 | Retr | 135 | BR/LA | FFX/GEM based | ‐ | 76 | 29.7 | ‐ | |
| Michelokos 29 | 2019 | Retr | 141 | BR/LA | FFX | ‐ | 80.6 | 37.7 | 18.6 | <.01 |
| Rangelova 190 | 2019 | Retr | 156 | BR/LA | FFX/others/CRT | 33.3 | ‐ | 22.4 | 12.7 | <.0001 |
| Byun 198 | 2019 | Retr | 337 | BR/LA/M | FFX | 18.0 | 7 | 21 | ‐ | |
| Bickenbach 174 | 2012 | Pros | ‐ | LA | ‐ | ‐ | 83 | 30 | ‐ | |
| Strobel 175 | 2012 | Pros | 257 | LA | CT/CRT | 47 | 35 | 12.7 | 8.8 | <.0001 |
| Herman 178 | 2015 | Pros | 49 | LA | GEM + RT | 8.0 | 100 | 22.2 | 13.8 | .182 |
| Marthey 180 | 2015 | Pros | 77 | LA | FFX | 36.0 | 89 | 24.9 | ‐ | |
| Sherman 182 | 2015 | Pros | 45 | LA | GTX/GX + CRT | 64.4 | 69 | ‐ | ‐ | |
| Sadot 179 | 2015 | Retr | 101 | LA | FFX | 31.0 | 55 | n.r. | ‐ | |
| Bednar 183 | 2017 | Retr | 92 | LA | FFX/GnP/others | 20.0 | ‐ | 32 | 14.3 | .0002 |
| Lee 188 | 2018 | Retr | 64 | LA | FFX | 23.0 | 73.3 | n.r. | 13 | |
| Gemenetzis 187 | 2019 | Retr | 415 | LA | FFX based/GEM based/others | 20.0 | 89.0 | 35.3 | 16.2 | .001 |
| Murphy 191 | 2019 | Pros | 49 | LA | FFX + Losartan | 69.0 | 88 | 31.4 | ‐ | |
| Napolitano 193 | 2019 | Retr | 56 | LA | FFX | 40.0 | 1.43 | 96.0 | 72.1 | .0006 |
| GnP | 28.6 | 83.3 | 62.6 | 53.3 | .0166) | |||||
| Satoi 176 | 2013 | Retr | 159 | LA/M | Multi | ‐ | ‐ | 39.7 | 20.8 | <.0001 |
| Opendro 177 | 2014 | Retr | 130 | LA/M | Multi | 10.0 | 84.6 | 36 | 9 | <.001 |
| Hackert 26 | 2016 | Pros | 575 | LA/M | FFX/GEM + RT/others | 50.8 | 75.0 | 15.3 | 8.5 | <.0001 |
| Asano 185 | 2018 | Retr | ‐ | LA/M | Multi | ‐ | 88.2 | 63 | ‐ | |
| Heger 32 | 2019 | Retr | 318 | LA/M | FFX | 52.0 | ‐ | 23 | ‐ | |
| Natsume 186 | 2019 | Retr | 434 | LA/M | FFX/GnP | 4.1 | 88.9 | n.r. | 11 | <.001 |
| Klaiber 33 | 2019 | Retr | ‐ | LA/M | FFX/GEM based/others | ‐ | 64.6 | 25.1 | ‐ | |
| Crippa 194 | 2016 | Retr | 127 | M | Multi | 8.7 | 82 | 39 | 11 | <.0001 |
| Wright 195 | 2016 | Retr | 1147 | M | FFX | 2.0 | 91.3 | 34.1 | ‐ | |
| Satoi 196 | 2017 | Pros | 33 | M | S‐1 + PTX (iv + ip) | 24.0 | ‐ | 26 | 14.2 | .0038 |
| Frigerio 197 | 2017 | Retr | 535 | M | FFX | 4.5 | 88 | 56 | ‐ | |
| Tanaka 34 | 2019 | Retr | 101 | M | FFX | 43.0 | 51 | 21.9 | 16.4 | .006 |
Abbreviations: BR, borderline resectable pancreatic cancer; CRT, chemoradiotherapy; CT, chemotherapy; FFX, FOLFIRINOX; GEM, gemcitabine; GnP, gemcitabine + nab‐paclitaxel; GTX, gemcitabine + docetaxel; GX, gemcitabine + capecitabine; i.p., intraperitoneal infusion; i.v., intravenous infusion; LA, locally advanced unresectable pancreatic cancer; M, metastatic pancreatic cancer; mo, months; MST, median survival time; Multi, multiple regimen; Pros, prospective study; PTX, paclitaxel; Retr, retrospective study; RT, radiation; SBRT, stereotactic body radiotherapy; UR, unresectable pancreatic cancer.